Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Divaya Bhutani, Shami Chakrabarti, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Markus Mapara, Abhinav Deol, Joseph Uberti, Ran Reshef

Blood (2025) 146 (Supplement 1): 4062.

https://doi.org/10.1182/blood-2025-4062

Published: 2025

Journal Articles

Development of a high-affinity antibody specific to the predominant λ light chain amyloid subtype for AL amyloidosis immunotherapy

Michael Hughes, Gavreel Kalantarov, Jing Fu, Miroslav Sekulic, Glen Markowitz, Josefine Krüger, Guifen Liu, HuiHui Ma, Markus Mapara, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 576.

https://doi.org/10.1182/blood-2025-576

Published: 2025

Journal Articles

Correction of ineffective erythropoiesis and durable clinical benefit with exagamglogene autotemcel for transfusion-dependent β-thalassemia

Blood (2025) 146 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2025-6089

Published: 2025

Journal Articles

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

Blood (2025) 146 (Supplement 1): 2532.

https://doi.org/10.1182/blood-2025-2532

Published: 2025

Journal Articles

Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121

Blood (2025) 146 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2025-2537

Published: 2025

Journal Articles

CRISPR-Cas12a gene editing of the HBG1/2 promoters leads to sustained normalization of total hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease: Updated Results from the RUBY trial

Blood (2025) 146 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2025-4314

Published: 2025

Journal Articles

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Simon Zhen, Divaya Bhutani, Mathew Maurer, Karan Wats, Yevgeniy Brailovsky, Michael Hughes, Jai Radhakrishnan, Markus Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5740.

https://doi.org/10.1182/blood-2025-5740

Published: 2025

Journal Articles

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Michael Hughes, Yiran Peng, Shikun Wang, Andrew Laine, Jai Radhakrishnan, Metodi Balev, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2025-5756

Published: 2025

Journal Articles

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis

Jing Fu, Huihui Ma, Gavreel Kalantarov, Michael Hughes, Guifen Liu, Markus Mapara, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 3919.

https://doi.org/10.1182/blood-2025-3919

Published: 2025

Journal Articles

Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR-T

Elisha Pinker, Christian Gordillo, David Sabatino, Hei Ton Chan, Pawel Muranski, Tamna Wangjam, Markus Mapara, Ran Reshef

Blood (2025) 146 (Supplement 1): 5884.

https://doi.org/10.1182/blood-2025-5884

Published: 2025

Journal Articles

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Abdul-Hamid Bazarbachi, HuiHui Ma, Simon Zhen, Miriam Klahr, Diane M. George, Christian Gordillo, Samuel Pan, Amer Assal, Andrew Eisenberger, David Diuguid, Ran Reshef, Suzanne Lentzsch, Divaya Bhutani, Rajshekhar Chakraborty, Monica Bhatia, Markus Mapara

Blood (2025) 146 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2025-4255

Published: 2025

Journal Articles

Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

Rabi Hanna, Haydar Frangoul, Christopher McKinney, Luis Pineiro, Markus Mapara, Jignesh Dalal, Hemalatha Rangarajan, Harold Atkins, Kai-Hsin Chang, Baisong Mei, Olubunmi Afonja, Mark C. Walters

Blood (2024) 144 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2024-210343

Published: 2024

Journal Articles

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Michael Sang Hughes, Metodi Balev, Jai Radhakrishnan, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2024) 144 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2024-209301

Published: 2024

Journal Articles

An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel

Stacey Rifkin-Zenenberg, Julie Kanter, Melissa A. Kinney, Janet L. Kwiatkowski, Robert S. Nickel, Mark C. Walters, Suhag Parikh, Alexis Thompson, Anil P. George, Markus Mapara, Paul L. Martin, Anjulika Chawla, Ankit Lodaya, Lin Pan, Emily Sheldon-Waniga, Francis J. Pierciey, Jr., John Tisdale, Ashish O. Gupta

Blood (2024) 144 (Supplement 1): 511.

https://doi.org/10.1182/blood-2024-199743

Published: 2024

Journal Articles

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Jing Fu, Huihui Ma, Shirong Li, Michael Sang Hughes, Gavreel Kalantarov, Guifen Liu, Markus Mapara, Suzanne Lentzsch

Blood (2024) 144 (Supplement 1): 360.

https://doi.org/10.1182/blood-2024-202091

Published: 2024

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Rabi Hanna, Haydar Frangoul, Christopher McKinney, Luis Pineiro, Markus Mapara, Jignesh Dalal, Kai-Hsin Chang, Michael Jaskolka, Keunpyo Kim, Daphne L. Farrington, Maha Wally, Baisong Mei, Adebayo Lawal, Olubunmi O. Afonja, Mark C. Walters

Blood (2023) 142 (Supplement 1): 4996.

https://doi.org/10.1182/blood-2023-187397

Published: 2023

Journal Articles

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Michael Sang Hughes, Siyang Leng, Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Shahzad Raza, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6576.

https://doi.org/10.1182/blood-2023-182842

Published: 2023

Journal Articles

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Ran Reshef, Mathew S Maurer, Jai Radhakrishnan, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2023-187214

Published: 2023

Journal Articles

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Jing Fu, Shirong Li, Guifen Liu, Huihui MA, Christophe Marcireau, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6618.

https://doi.org/10.1182/blood-2023-190740

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Development of a high-affinity antibody specific to the predominant λ light chain amyloid subtype for AL amyloidosis immunotherapy

Correction of ineffective erythropoiesis and durable clinical benefit with exagamglogene autotemcel for transfusion-dependent β-thalassemia

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121

CRISPR-Cas12a gene editing of the HBG1/2 promoters leads to sustained normalization of total hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease: Updated Results from the RUBY trial

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis

Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR-T

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only